title: Thirty-day mortality after peptic ulcer bleeding in hospitalized patients receiving low-dose aspirin at time of admission.
abstract: BACKGROUND
  Use of low-dose aspirin increases the risk for peptic ulcer bleeding (PUB) by approximately 60%. However, whether use of low-dose aspirin influences the outcome of PUB is not known.
  
  
  OBJECTIVE
  The aim of this study was to examine the effect of low-dose aspirin use at the time of hospital admission on 30-day mortality among hospitalized PUB patients.
  
  
  METHODS
  This population-based study was conducted using data from the hospital discharge registries in the Danish counties of North Jutland, Aarhus, and Viborg. We identified all hospitalized patients with a first-time diagnosis of PUB and their comorbidities between 1991 and 2003. This information was linked with data from the counties' prescription databases and the Danish Civil Registration System to determine the preadmission use of low-dose aspirin (75 or 150 mg) and mortality within 30 days after admission. We calculated mortality ratios (MRs) according to the use of low-dose aspirin, adjusted for age, sex, comorbidity, alcoholism, and use of other PUB-associated or antiulcer drugs.
  
  
  RESULTS
  We identified 7204 patients with a discharge diagnosis of PUB (3751 men, 3453 women; median age, 71 years [interquartile range, 62-82 years]). The overall mortality within 30 days after admission with PUB was 10.7%. Among all patients with PUB, 1029 (14.3%) were current (ie, at the time of admission) users of low-dose aspirin and 709 (9.8%) were former low-dose aspirin users, respectively. Compared with those who never used lowdose aspirin, current users had an adjusted 30-day MR of 0.83 (95% CI, 0.68-1.01).
  
  
  CONCLUSIONS
  The results of this follow-up study suggest that current use of low-dose aspirin was not associated with increased mortality in these hospitalized patients with PUB.
authors.affiliation: Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: Hanne
authors.initials: H
authors.lastname: Mose
authors.forename: Mette
authors.initials: M
authors.lastname: Larsen
authors.forename: Anders
authors.initials: A
authors.lastname: Riis
authors.forename: Søren Paaske
authors.initials: SP
authors.lastname: Johnsen
authors.forename: Reimar Wernich
authors.initials: RW
authors.lastname: Thomsen
authors.forename: Henrik Toft
authors.initials: HT
authors.lastname: Sørensen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D009735:Nursing Homes; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced* / Q000401:mortality*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin